Premium
Comparable endemic coronavirus nucleoprotein‐specific antibodies in mild and severe Covid‐19 patients
Author(s) -
Leach Susannah,
Harandi Ali M.,
Bergström Tomas,
Andersson LarsMagnus,
Nilsson Staffan,
Hoek Lia,
Gisslén Magnus
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.27038
Subject(s) - virology , nucleoprotein , covid-19 , coronavirus , antibody , biology , betacoronavirus , severe acute respiratory syndrome coronavirus , coronavirus infections , medicine , virus , immunology , outbreak , infectious disease (medical specialty) , disease , pathology
The severity of disease of Covid‐19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross‐reactive immune responses between SARS‐CoV‐2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV nucleoprotein (N)‐specific antibodies in the sera of patients with mild or severe Covid‐19 are associated with Covid‐19 severity. There were comparable levels of eCoV N‐specific antibodies early and during the first month of infection in Covid‐19 patients with mild and severe symptoms, and healthy SARS‐CoV‐2‐negative subjects. These results warrant further studies to investigate the potential role of eCoV‐specific antibodies in immunity to SARS‐CoV‐2 infection.